$LXRX
LEXICON PHARMACEUTICALS, INC.

2012 Q4 Form 10-Q Financial Statement

#000106282212000050 Filed on November 07, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q4
Revenue $218.0K $372.0K $343.0K
YoY Change -36.44% 4.79% -73.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.900M $4.400M $4.000M
YoY Change -2.5% 7.32% 2.56%
% of Gross Profit
Research & Development $21.00M $19.19M $28.10M
YoY Change -25.27% -2.36% 53.55%
% of Gross Profit
Depreciation & Amortization $900.0K $1.100M $1.100M
YoY Change -18.18% -8.33% -15.38%
% of Gross Profit
Operating Expenses $24.70M $29.43M $33.70M
YoY Change -26.71% 13.0% 42.19%
Operating Profit -$24.49M -$29.06M -$33.34M
YoY Change -26.54% 13.11%
Interest Expense -$500.0K $527.0K -$500.0K
YoY Change 0.0% -5.89% -16.67%
% of Operating Profit
Other Income/Expense, Net $100.0K $4.000K $0.00
YoY Change -95.45%
Pretax Income -$24.90M -$29.50M -$33.80M
YoY Change -26.33% 13.01% 46.96%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$24.87M -$29.54M -$33.85M
YoY Change -26.51% 13.16% 47.15%
Net Earnings / Revenue -11409.63% -7940.59% -9867.35%
Basic Earnings Per Share
Diluted Earnings Per Share -$343.4K -$421.4K -$676.0K
COMMON SHARES
Basic Shares Outstanding 512.4M shares 494.3M shares 337.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $222.8M $206.4M $281.3M
YoY Change -20.8% 43.63% 33.25%
Cash & Equivalents $30.42M $20.76M $186.3M
Short-Term Investments $192.4M $185.7M $95.00M
Other Short-Term Assets $6.349M $9.004M $3.748M
YoY Change 69.4% 107.61% 30.0%
Inventory
Prepaid Expenses
Receivables $1.378M $233.0K $350.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $230.9M $216.1M $285.8M
YoY Change -19.19% 45.04% 33.09%
LONG-TERM ASSETS
Property, Plant & Equipment $42.63M $43.52M $46.42M
YoY Change -8.15% -8.09% -13.12%
Goodwill $44.54M $44.54M $44.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles $53.56M $53.56M $53.56M
YoY Change 0.0% 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $109.0K $135.0K $205.0K
YoY Change -46.83% -51.96% -66.88%
Total Long-Term Assets $140.8M $141.8M $144.7M
YoY Change -2.68% -2.73% -4.88%
TOTAL ASSETS
Total Short-Term Assets $230.9M $216.1M $285.8M
Total Long-Term Assets $140.8M $141.8M $144.7M
Total Assets $371.8M $357.8M $430.5M
YoY Change -13.64% 21.42% 17.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.661M $4.306M $6.042M
YoY Change 26.8% -22.08% 91.26%
Accrued Expenses $8.922M $12.78M $13.79M
YoY Change -35.28% 65.94% 120.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.574M $1.542M $1.443M
YoY Change 9.08% 9.13% 26.8%
Total Short-Term Liabilities $18.29M $19.05M $21.39M
YoY Change -14.52% 28.67% 98.52%
LONG-TERM LIABILITIES
Long-Term Debt $21.88M $22.28M $23.45M
YoY Change -6.71% -6.47% -14.24%
Other Long-Term Liabilities $32.28M $31.09M $55.15M
YoY Change -41.46% -42.04% 13.04%
Total Long-Term Liabilities $54.16M $53.37M $78.60M
YoY Change -31.09% -31.1% 3.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.29M $19.05M $21.39M
Total Long-Term Liabilities $54.16M $53.37M $78.60M
Total Liabilities $105.1M $105.1M $132.9M
YoY Change -20.94% -16.09% 10.92%
SHAREHOLDERS EQUITY
Retained Earnings -$899.8M -$875.0M -$789.6M
YoY Change 13.96% 15.77% 17.26%
Common Stock $512.0K $495.0K $480.0K
YoY Change 6.67% 46.45% 42.01%
Preferred Stock
YoY Change
Treasury Stock (at cost) $630.0K $630.0K $345.0K
YoY Change 82.61% 82.61% 45.57%
Treasury Stock Shares 380.0K shares 380.0K shares 218.0K shares
Shareholders Equity $266.7M $252.8M $297.6M
YoY Change
Total Liabilities & Shareholders Equity $371.8M $357.8M $430.5M
YoY Change -13.64% 21.42% 17.34%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q4
OPERATING ACTIVITIES
Net Income -$24.87M -$29.54M -$33.85M
YoY Change -26.51% 13.16% 47.15%
Depreciation, Depletion And Amortization $900.0K $1.100M $1.100M
YoY Change -18.18% -8.33% -15.38%
Cash From Operating Activities -$20.50M -$25.00M -$22.50M
YoY Change -8.89% 23.76% 15.98%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$100.0K -$200.0K
YoY Change -50.0% -50.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$6.600M $11.70M $18.30M
YoY Change -136.07% -62.14% -112.64%
Cash From Investing Activities -$6.700M $11.60M $18.10M
YoY Change -137.02% -62.21% -112.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 36.80M 500.0K 160.3M
YoY Change -77.04% -225.0% -80250.0%
NET CHANGE
Cash From Operating Activities -20.50M -25.00M -22.50M
Cash From Investing Activities -6.700M 11.60M 18.10M
Cash From Financing Activities 36.80M 500.0K 160.3M
Net Change In Cash 9.600M -12.90M 155.9M
YoY Change -93.84% -227.72% -194.66%
FREE CASH FLOW
Cash From Operating Activities -$20.50M -$25.00M -$22.50M
Capital Expenditures -$100.0K -$100.0K -$200.0K
Free Cash Flow -$20.40M -$24.90M -$22.30M
YoY Change -8.52% 24.5% 16.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6042000 USD
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4306000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
350000 USD
CY2012Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
233000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13786000 USD
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12782000 USD
CY2012Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
83412000 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
80535000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000 USD
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000 USD
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1127832000 USD
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1087033000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4905000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4354000 USD
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1400000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4900000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4400000 USD
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1600000 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2012Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2012Q3 us-gaap Assets
Assets
357835000 USD
CY2011Q4 us-gaap Assets
Assets
430512000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
285790000 USD
CY2012Q3 us-gaap Assets Current
AssetsCurrent
216085000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186309000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20759000 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30521000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47208000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16687000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-165550000 USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
495000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
480000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82341000 USD
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26140000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29498000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-85338000 USD
CY2011Q3 us-gaap Contracts Revenue
ContractsRevenue
335000 USD
CY2012Q3 us-gaap Contracts Revenue
ContractsRevenue
214000 USD
us-gaap Contracts Revenue
ContractsRevenue
1312000 USD
us-gaap Contracts Revenue
ContractsRevenue
565000 USD
CY2012Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0823
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
119000 USD
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
421000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14212000 USD
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
13910000 USD
CY2012Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18745000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18745000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3274000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3752000 USD
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Investment Income Interest
InvestmentIncomeInterest
158000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
5198000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
10087000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-35000000 USD
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
30120000 USD
CY2011Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
55033000 USD
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
53465000 USD
CY2010Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
48267000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13340000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4396000 USD
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4055000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13123000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2012Q3 us-gaap Goodwill
Goodwill
44543000 USD
CY2012Q3 us-gaap Guarantee Obligations Maximum Exposure
GuaranteeObligationsMaximumExposure
2000000 USD
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
44000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
215000 USD
CY2011Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
60000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
132944000 USD
us-gaap Interest Paid Net
InterestPaidNet
1925000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
706000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3824000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1887000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-117000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-255000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
50000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
70000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
338000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5256000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1454000 USD
CY2012Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53557000 USD
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53557000 USD
us-gaap Interest Expense
InterestExpense
1594000 USD
us-gaap Interest Expense
InterestExpense
1977000 USD
CY2011Q3 us-gaap Interest Expense
InterestExpense
560000 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
527000 USD
us-gaap Interest Paid Net
InterestPaidNet
1535000 USD
CY2012Q3 us-gaap Liabilities
Liabilities
105076000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
430512000 USD
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
357835000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21390000 USD
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19051000 USD
CY2011Q3 us-gaap Licenses Revenue
LicensesRevenue
20000 USD
CY2012Q3 us-gaap Licenses Revenue
LicensesRevenue
158000 USD
us-gaap Licenses Revenue
LicensesRevenue
194000 USD
us-gaap Licenses Revenue
LicensesRevenue
306000 USD
CY2011Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1443000 USD
CY2012Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
1542000 USD
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
23451000 USD
CY2012Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
22284000 USD
CY2004Q2 us-gaap Mortgage Loans On Real Estate New Mortgage Loans
MortgageLoansOnRealEstateNewMortgageLoans
34000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-444000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3163000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-91078000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
51923000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65447000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74028000 USD
us-gaap Net Income Loss
NetIncomeLoss
-85338000 USD
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-26103000 USD
us-gaap Net Income Loss
NetIncomeLoss
-82370000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-29539000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
29432000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
132923000 USD
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
26046000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
29000 USD
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3748000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
205000 USD
CY2011Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-37000 USD
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000 USD
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
us-gaap Operating Expenses
OperatingExpenses
84794000 USD
us-gaap Operating Expenses
OperatingExpenses
82259000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25691000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-80753000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-83923000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29060000 USD
CY2012Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9004000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
55146000 USD
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31086000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
145000 USD
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
88000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
108000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
285000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
151776000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
82625000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
997000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
379000 USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1055000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-146000 USD
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-874959000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-789621000 USD
CY2012Q3 us-gaap Revenues
Revenues
372000 USD
us-gaap Revenues
Revenues
1506000 USD
us-gaap Revenues
Revenues
871000 USD
CY2011Q3 us-gaap Revenues
Revenues
355000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63721000 USD
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19655000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61584000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19192000 USD
CY2011Q4 us-gaap Restricted Investments
RestrictedInvestments
430000 USD
CY2012Q3 us-gaap Restricted Investments
RestrictedInvestments
430000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
61070000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2622000 USD
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43515000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46417000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3244000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1068000 USD
CY2011Q3 lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
337678000 shares
CY2007Q2 lxrx Holdings Contribution To Icon
HoldingsContributionToIcon
45000000 USD
CY2010Q3 lxrx Lexicon Paid Holdings Cash
LexiconPaidHoldingsCash
10000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Discount Rate
SymphonyContingentPaymentDiscountRate
0.18
CY2007Q2 lxrx Lexicon Received Cash From Holdings
LexiconReceivedCashFromHoldings
15000000 USD
CY2007Q2 lxrx Lexicon Sold Shares To Holdings
LexiconSoldSharesToHoldings
7650622 shares
CY2012Q3 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
5844000 USD
lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
5198000 USD
lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
10087000 USD
CY2011Q3 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
2336000 USD
lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
35000000 USD
lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
0 USD
lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
483693000 shares
lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
337625000 shares
CY2011Q3 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
823000 USD
CY2012Q3 us-gaap Secured Debt
SecuredDebt
23800000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4354000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4905000 USD
CY2012Q3 us-gaap Short Term Investments
ShortTermInvestments
186089000 USD
CY2011Q4 us-gaap Short Term Investments
ShortTermInvestments
95383000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1055000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
552000 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
252759000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
297568000 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
297568000 USD
CY2012Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
252759000 USD
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
247024000 USD
CY2011Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
169481000 USD
CY2011Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
218000 shares
CY2012Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
380000 shares
CY2012Q3 us-gaap Treasury Stock Value
TreasuryStockValue
630000 USD
CY2011Q4 us-gaap Treasury Stock Value
TreasuryStockValue
345000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
108000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
285000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
29000 USD
lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
2480000 USD
CY2012Q3 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
923000 USD
CY2010Q3 lxrx Symphon Fair Value Of Base And Contingent Payments
SymphonFairValueOfBaseAndContingentPayments
45600000 USD
lxrx Symphony Base Payment Acceleration Of Expense
SymphonyBasePaymentAccelerationOfExpense
4300000 USD
CY2010Q3 lxrx Symphony Base Payment Discount Rate
SymphonyBasePaymentDiscountRate
0.14
CY2012Q3 lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
490049000 shares
CY2012Q3 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
669000 USD
lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
1874000 USD
lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
2030000 USD
CY2011Q3 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
609000 USD
lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
2875000 USD
CY2012Q3 lxrx Symphony Base Payment In Shares
SymphonyBasePaymentInShares
13237519 shares
CY2012Q3 lxrx Symphony Base Payment Obligation
SymphonyBasePaymentObligation
35000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Maximum
SymphonyContingentPaymentMaximum
45000000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001062822
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
512374359 shares
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name View Source Status
0001062822-12-000050-index-headers.html Edgar Link pending
0001062822-12-000050-index.html Edgar Link pending
0001062822-12-000050.txt Edgar Link pending
0001062822-12-000050-xbrl.zip Edgar Link pending
exh311certificationofprinc.htm Edgar Link pending
exh312certificationofprinc.htm Edgar Link pending
exh321certificationofprinc.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
lxrx-20120930.xml Edgar Link completed
lxrx-20120930.xsd Edgar Link pending
lxrx-20120930_cal.xml Edgar Link unprocessable
lxrx-20120930_def.xml Edgar Link unprocessable
lxrx-20120930_lab.xml Edgar Link unprocessable
lxrx-20120930_pre.xml Edgar Link unprocessable
lxrx930201210-q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending